Man Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Man Group’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,947	Closed	-$151K	–	2224
2023 Q2	$151K	Buy	+13,947	New	+$119K	﹤0.01%	1850
2023 Q1	–	Sell	-82,930	Closed	-$330K	–	2303
2022 Q4	$330K	Buy	82,930 +14,210	+21%	+$69.9K	﹤0.01%	1623
2022 Q3	$457K	Buy	+68,720	New	+$423K	﹤0.01%	1545

Other funds holding MRNS

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Man Group's MRNS Position: Q3 2023 in Review

Man Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2023, closing a stake of 13,947 shares — an estimated $151K sold.

Man Group first reported a position in MRNS in Q3 2022 and held it in 3 quarters. The position peaked at $457K in Q3 2022. 104 funds tracked by Wall St. Rank hold MRNS as of Q3 2023.

Man Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
Man Group sold 13,947 Marinus Pharmaceuticals, Inc shares in Q3 2023, an estimated $151K.
Man Group first reported a position in Marinus Pharmaceuticals, Inc in Q3 2022 and held it in 3 quarters.
Man Group's Marinus Pharmaceuticals, Inc position peaked at $457K in Q3 2022.
104 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.